Xiaolong Yan
Papers
1
Total Citations
53
H-Index
1
About
Xiaolong Yan is a leading clinical researcher in thoracic oncology, with a primary focus on neoadjuvant immunotherapy for resectable non-small cell lung cancer (NSCLC). His most cited work, a 2021 open-label, multicenter, single-arm study, investigates the combination of PD-1 inhibitors with chemotherapy prior to surgery. This landmark trial builds on the foundation of the CheckMate 159 trial—which established the promise of single-agent nivolumab—by demonstrating that combining immunotherapy with chemotherapy can yield even more robust pathological responses and potentially improve long-term survival outcomes. With over 50 citations, this study has significantly influenced the design of subsequent neoadjuvant protocols and clinical guidelines. Yan’s contributions are pivotal in the shift toward perioperative chemoimmunotherapy, helping to redefine the standard of care for early-stage NSCLC. His work not only advances the mechanistic understanding of immune checkpoint blockade in the preoperative setting but also provides actionable evidence for improving patient prognoses. For students and researchers in surgical oncology and immuno-oncology, Yan’s research exemplifies the translational power of rigorous, multicenter clinical trials.
Research Focus
Key Achievements
Top Papers
- 1